TickerTalks
Browse all tickers →
TickerTalks›$RGC
RGRGC

Regencell Bioscience Holdings Limited

Hot onTrending downwardX mentions rising faster than the marketMoving on elevated volume
$RGC·$4.2B·Drug Manufacturers - Specialty & Generic·Healthcare
$7.49-12.5%YTD-66.0%1Y+34368.5%
Mentions · last 7 days
2026-06-18: 1 posts2026-06-19: 4 posts2026-06-20: 6 posts2026-06-21: 4 posts2026-06-22: 23 posts2026-06-23: 30 posts2026-06-24: 17 posts109
Price updated 2h ago·X counts updated 1h ago
RGRGC
$RGCRegencell Bioscience Holdings Limited
$7.49-12.50%109 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $RGC, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-06-25

Falling on heavy selling — points lower unless it turns around.

Pre-revenue TCM biotech with class-action overhang — chart at 0.02% of 52-week range, today's 23% drop confirms the unwind.

Regencell Bioscience is a Hong Kong-listed Traditional Chinese Medicine biotech whose stock saw a massive promotional spike and is now in full unwind — Pomerantz, Rosen, and Bronstein Gewirtz securities-class-action investigations have all filed in recent weeks.

Where it stands:

  • Trailing twelve-month revenue is essentially zero with operating margins running at -442% and quarterly EPS losses ranging $-0.0035 to $-0.0107 — there is no commercial business; this has been a chart phenomenon, not a fundamentals story.
  • Three separate securities-class-action investigations (Pomerantz, Rosen, Bronstein Gewirtz) have been filed in the recent window — this is unusually heavy legal density for a single name and usually correlates with continued chart weakness.
  • Insider activity is just two small director D-Return events ($4.7K and $59K) — administrative, not material in either direction.
  • At 0.02% of the 52-week range and 65% below the 50-day with today's 23% drop on 3.5x average volume, the chart is in full classic-pump-unwind pattern.

Trajectory is breaking-down — at the absolute bottom of the trading range with no completed base. Any meaningful TCM-clinical-data readout or favorable class-action resolution restarts the move; absent a specific catalyst, the unwind dynamic continues for this kind of post-pump biotech.

What to watch: Any TCM clinical-trial data readout, securities-class-action lead-plaintiff motions and complaint detail, and the next quarterly disclosure. Absent a specific catalyst, the post-pump unwind dynamic continues for this kind of biotech.

pump unwindlitigation overhang

Read the AI verdict + X sentiment for $RGC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $RGC.

Drug Manufacturers - Specialty & Generic · Healthcare

Zoetis faces structural uncertainty — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate is whether volume softness is cyclical (pet owners deferring discretionary vet visits) or structural (GLP-1 drugs potentially reducing obesity-related pet conditions long-term).

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+12.8%YTD
+45.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-602.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-444%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-232%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Jun 15, 2026$-0.01——
Q3 2025Nov 18, 2025$-0.00——
Q1 2025Jun 26, 2025$-0.14——
Q4 2023Jan 26, 2024$0.00——

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.01—
Q4 FY25$0———$-0.00$0
Q2 FY25$0———$-0.00$0
Q4 FY24$0-100.0%——$-0.00$-2.0M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-65.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-61.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.645-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 2 other (2 returns) in window

See when $RGC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)May 19424B5
424B5Prospectus supplement (offering)Mar 30424B5
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
+ 10 other (8 6-Ks · 1 F-3ASR · 1 3) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGCglobenewswire.com·2d agoBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harmprnewswire.com·2d agoRegencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rightsgurufocus.com·2d agoRegencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rightsbusinesswire.com·2d agoBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harmfeeds.newsfilecorp.com·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$INDV$BGM
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport